Cargando…

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients

BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare condition that can ultimately lead to right heart failure and death. In this study we estimated the health care costs and resource utilization associated with PAH in a large US managed care health plan. METHODS: Subjects with claims-based e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sikirica, Mirko, Iorga, Serban R, Bancroft, Tim, Potash, Jesse
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301626/ https://www.ncbi.nlm.nih.gov/pubmed/25539602 http://dx.doi.org/10.1186/s12913-014-0676-0

Ejemplares similares

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)
por: Tsang, Yuen, et al.
Publicado: (2023)

Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients
por: Bonner, Nicola, et al.
Publicado: (2013)

Symptom phenotypes in pulmonary arterial hypertension: The PAH “symptome”
por: Matura, Lea Ann, et al.
Publicado: (2022)

The economic burden of pulmonary arterial hypertension in Spain
por: Zozaya, Néboa, et al.
Publicado: (2022)

Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application
por: Al-Hilal, Taslim A., et al.
Publicado: (2020)

Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
por: Steele, Peter, et al.
Publicado: (2010)

Incremental Health Care Resource Utilization and Economic Burden of Venous Thromboembolism Recurrence from a U.S. Payer Perspective
por: Lin, J., et al.
Publicado: (2014)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH
por: McCollister, Deborah, et al.
Publicado: (2016)

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City
por: Sulica, Roxana, et al.
Publicado: (2021)

The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia
por: Morrisroe, Kathleen, et al.
Publicado: (2019)

Sickle Cell Disease (SCD) Leading to Pulmonary Arterial Hypertension (PAH) and Cholelithiasis (CL)
por: Chacko, Saran, et al.
Publicado: (2023)

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
por: Cicin, Irfan, et al.
Publicado: (2021)

The exercise in pulmonary arterial hypertension (ExPAH) study: A randomized controlled pilot of exercise training and multidisciplinary rehabilitation in pulmonary arterial hypertension
por: Chia, Karen S. W., et al.
Publicado: (2022)

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)
por: Preston, Ioana R., et al.
Publicado: (2015)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Usefulness of Red Cell Width Distribution (RDW) in the Assessment of Children with Pulmonary Arterial Hypertension (PAH)
por: Zuk, Malgorzata, et al.
Publicado: (2019)

Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH)
por: Argula, Rahul G, et al.
Publicado: (2019)

The burden of comorbidities in pulmonary arterial hypertension
por: Lang, Irene M, et al.
Publicado: (2019)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
por: Idrees, Majdy, et al.
Publicado: (2015)

Acute Deterioration of Pulmonary Arterial Hypertension (PAH) in a Patient with Neurofibromatosis Type 1 (NF1)
por: Tanaka, Seiya, et al.
Publicado: (2019)

Risk assessment in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study
por: Wang, Qian, et al.
Publicado: (2022)

Pulmonary Arterial Hypertension (PAH) as the Initial Manifestation of Systematic Lupus Erythematosus (SLE): A Rare Presentation
por: Kamath, Sangita D, et al.
Publicado: (2023)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

Which Functional Classification Scale is Optimal for Children with Pulmonary Hypertension (PAH)?
por: Migdał, Anna, et al.
Publicado: (2020)

The inpatient burden of abdominal and gynecological adhesiolysis in the US
por: Sikirica, Vanja, et al.
Publicado: (2011)

Epigenetics of hypoxic pulmonary arterial hypertension following intrauterine growth retardation rat: epigenetics in PAH following IUGR
por: Xu, Xue-Feng, et al.
Publicado: (2013)

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document
por: Rahaghi, Franck F., et al.
Publicado: (2017)

Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH
por: Rabacal, Whitney, et al.
Publicado: (2019)

Activation of renin–angiotensin–aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats
por: Yuan, Yi-Ming, et al.
Publicado: (2015)

A prognostic model for systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study
por: Qu, Jingge, et al.
Publicado: (2023)

Payer perceptions on the use of economic models in oncology decision making
por: Biskupiak, Joseph, et al.
Publicado: (2021)

Benchmarking HIV Quality Measures Across US Payer Types
por: Priest, Julie L., et al.
Publicado: (2020)

Arrhythmic Burden and Outcomes in Pulmonary Arterial Hypertension
por: Middleton, Jennifer T., et al.
Publicado: (2019)

Hospital burden of pulmonary arterial hypertension in France
por: Bergot, Emmanuel, et al.
Publicado: (2019)

Comparing the burden of illness in patients with alopecia areata vs atopic dermatitis in the US population from a payer perspective
por: Fenske, D. Christian, et al.
Publicado: (2023)

Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
por: Moser, Bernhard, et al.
Publicado: (2014)

Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH
por: Eichstaedt, Christina A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0bq9ri35b04unpc0b68d0t1jab